CPHI Milan 2026

CPHI Milan 2026

Event Details

Regulatory Updates

Last update: 11 Jan 2024

Year	Product	Update

2026	Empagliflozin	EU DMF
	Ibrutinib	EU DMF
	Pirtobrutinib	US DMF
	Ferric Carboxymaltose	US DMF
	Fidaxomicin	US DMF
	Fidaxomicin	EU DMF
	Mavacamten	US DMF
	Zavegepant	US DMF
	Ixazomib Citrate	US DMF
	Voclosporin	EU DMF
	Edoxaban Tosylate	CA DMF
	Capmatinib Dihydrochloride Monohydrate	US DMF
	Samidorphan	US DMF
	Finerenone	US DMF
	Nilotinib Tartrate	EU DMF

2025	Migalastat	EU DMF
	Semaglutide	EU DMF
	Paliperidone Palmitate	US DMF
	Ferric Carboxymaltose	EU DMF
	Tirzepatide	US DMF
	Semaglutide	US DMF
	Tapinarof	US DMF
	Midostaurin	BR DMF
	Apixaban	CA DMF
	Pacritinib Citrate	US DMF
	Azacitidine	EU DMF
	Midostaurin	EU DMF
	Sotorasib	US DMF
	Belumosudil	US DMF
	Palbociclib	EU DMF
	Apixaban	EU DMF

2024	Sugammadex Sodium	CADIFA
	Clascoterone	US DMF
	Risdiplam	US DMF
	Nintedanib Esylate	EU DMF
	Trilaciclib	US DMF
	Tafamidis Meglumine	CA DMF
	Triheptanoin	US DMF

2023	Fluticasone Furoate	US DMF
	Edoxaban Tosylate	CN DMF
	Rivaroxaban	CADIFA
	Tucatinib	US DMF
	Eltrombopag Olamine	Brazil DMF
	Valsartan Sacubitril	US DMF
	Sugammadex Sodium	CN DMF

2022	Edoxaban Tosylate	EU DMF
	Memantine HCl	CADIFA

Contact us

Step 1 of

First name*

Last name*

Business email*

Company*

Job title*

Country*

I'm interested in*

Segment of interest*

Tell us more about your project

Select product*

Formulation

Project type*

Target market

Quantity

Comments

Disclaimer: This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.

By clicking submit, you are agreeing to our Privacy Policy